Patent · US Active

Formulation of a pan-JAK inhibitor

US11795180B2 · kind B2 · utility

0Cited by

1References

24Claims

0Family size

Assignee

Theravance Biopharma R&D IP, LLC · US

Inventors

Bernardus Joseph Nitert · Dieden, NL
Yvonne Rosiaux · Rijkevorsel, BE
Marian E. Van Der Veen · Eindhoven, NL
Nathan Schulpen · Ekeren, BE
Jens Maes · Herentals, BE
Guido Alfons F. Verniest · Beerse, BE
Venkat R. Thalladi · Foster City, US
Ai Ling Ching · San Francisco, US

Key dates

Filing date	Oct 7, 2021
Grant date	Oct 24, 2023
Priority date	—
Expiry date	Oct 23, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to pharmaceutical compositions comprising (3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile), methods of use thereof, and methods of preparation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.